Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients
D. Zanon,
U.M. Musazzi,
A. Manca,
A. De Nicolò,
A. D'Avolio,
F. Cilurzo,
N. Maximova,
C. Tomasello,
E. Clementi,
P. Minghetti
Affiliations
D. Zanon
Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy
U.M. Musazzi
Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan, Italy
A. Manca
Laboratory of Clinical Pharmacology and Pharmacogenetics, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy
A. De Nicolò
Laboratory of Clinical Pharmacology and Pharmacogenetics, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy
A. D'Avolio
Laboratory of Clinical Pharmacology and Pharmacogenetics, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy
F. Cilurzo
Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan, Italy
N. Maximova
Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy
C. Tomasello
S.C. Farmacie Ospedaliere - Ospedale M. Vittoria - Asl Città di Torino, Turin, Italy
E. Clementi
Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences “Luigi Sacco”, L. Sacco University Hospital, Università di Milano, Milan, Italy
P. Minghetti
Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan, Italy; Corresponding author.
The COVID-19 outbreak is now one of the most critical crises to manage for most of national healthcare systems in the world. The situation is complicated by the absence of vaccines and authorized pharmacological treatments, except for remdesivir. In this context, many medicaments, including different Ebola and HIV antivirals, are used off-label in the hospital wards as life-treating medicines for COVID-19 patients. Authorized medicaments manipulation is sometimes necessary because they are not always formulated to be administered to non-cooperative patients or they are in shortage. It is this the case of the fixed combination of lopinavir/ritonavir, which was extensively used in the first phase of the outbreak inducing a shortage of the oral solution available in the EU market. This work provides data on size distribution, osmolarity other than drug chemical stability of a lopinavir/ritonavir extemporaneous preparation made by using the solid dosage form (i.e., tablet) available on the market as drug source. The reported data indicate that such preparation is suitable to be delivered through a nasogastric tube, and enough stable for two weeks from the preparation at room temperature.
